• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Addition of Daratumumab to First-Line Therapy of Newly Diagnosed Multiple Myeloma in Patients Eligible for Autologous Stem Cell Transplantation: A Single-Center Real-Life Experience.

作者信息

Olivari Edoardo, Paris Laura, Stefanoni Paola, Pavoni Chiara, Rambaldi Alessandro, Galli Monica

机构信息

University of Milan, Italy.

Department of Oncology and Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy.

出版信息

Mediterr J Hematol Infect Dis. 2025 May 1;17(1):e2025040. doi: 10.4084/MJHID.2025.040. eCollection 2025.

DOI:10.4084/MJHID.2025.040
PMID:40375903
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12081041/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d15/12081041/a4baa1685df4/mjhid-17-1-e2025040f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d15/12081041/41e610079b96/mjhid-17-1-e2025040f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d15/12081041/a4baa1685df4/mjhid-17-1-e2025040f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d15/12081041/41e610079b96/mjhid-17-1-e2025040f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d15/12081041/a4baa1685df4/mjhid-17-1-e2025040f2.jpg

相似文献

1
Addition of Daratumumab to First-Line Therapy of Newly Diagnosed Multiple Myeloma in Patients Eligible for Autologous Stem Cell Transplantation: A Single-Center Real-Life Experience.在适合自体干细胞移植的新诊断多发性骨髓瘤患者的一线治疗中添加达雷妥尤单抗：单中心真实世界经验
Mediterr J Hematol Infect Dis. 2025 May 1;17(1):e2025040. doi: 10.4084/MJHID.2025.040. eCollection 2025.
2
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.硼替佐米、沙利度胺和地塞米松联合或不联合达雷妥尤单抗用于新诊断多发性骨髓瘤患者自体造血干细胞移植前后（CASSIOPEIA）：一项随机、开放标签、3 期研究。
Lancet. 2019 Jul 6;394(10192):29-38. doi: 10.1016/S0140-6736(19)31240-1. Epub 2019 Jun 3.
3
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.在新诊断的多发性骨髓瘤中，用包含达雷妥尤单抗和来那度胺的四联诱导治疗进行干细胞动员的结果：来自 MASTER 和 GRIFFIN 试验的结果。
Transplant Cell Ther. 2023 Mar;29(3):174.e1-174.e10. doi: 10.1016/j.jtct.2022.11.029. Epub 2022 Dec 6.
4
Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma.达雷妥尤单抗：一种适合移植的新诊断多发性骨髓瘤联合治疗药物的评价。
Drugs. 2020 Sep;80(14):1455-1464. doi: 10.1007/s40265-020-01385-x.
5
Impact of quadruplet induction therapy on stem cell mobilization yields in newly diagnosed multiple myeloma.四联诱导疗法对新诊断多发性骨髓瘤患者干细胞动员产量的影响
Transfus Clin Biol. 2025 May;32(2):195-198. doi: 10.1016/j.tracli.2025.02.001. Epub 2025 Feb 13.
6
[Daratumumab maintenance after autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma].[达雷妥尤单抗用于新诊断多发性骨髓瘤自体造血干细胞移植后的维持治疗]
Zhonghua Xue Ye Xue Za Zhi. 2023 Dec 14;44(12):1016-1021. doi: 10.3760/cma.j.issn.0253-2727.2023.12.008.
7
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.达雷妥尤单抗联合来那度胺、硼替佐米和地塞米松用于适合移植的新诊断多发性骨髓瘤患者（GRIFFIN）：一项开放标签、随机、2 期试验的最终分析。
Lancet Haematol. 2023 Oct;10(10):e825-e837. doi: 10.1016/S2352-3026(23)00217-X. Epub 2023 Sep 11.
8
Successful treatment with daratumumab, lenalidomide, and dexamethasone therapy followed by autologous stem cell transplantation for newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome: a case report.采用达雷妥尤单抗、来那度胺和地塞米松联合治疗，随后进行自体造血干细胞移植治疗新诊断的多发性神经病、器官肿大、内分泌病、M 蛋白、皮肤改变综合征：一例报告。
J Med Case Rep. 2022 Aug 18;16(1):311. doi: 10.1186/s13256-022-03552-y.
9
Stem Cell Mobilization for Multiple Myeloma Patients Receiving Daratumumab-Based Induction Therapy: A Real- World Experience.接受基于达雷妥尤单抗诱导治疗的多发性骨髓瘤患者的干细胞动员：一项真实世界经验
Transplant Cell Ther. 2023 May;29(5):340.e1-340.e4. doi: 10.1016/j.jtct.2023.02.013. Epub 2023 Feb 19.
10
Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma.与单独使用达雷妥尤单抗、泊马度胺和地塞米松（DPd）相比，对于复发难治性多发性骨髓瘤患者，采用达雷妥尤单抗、泊马度胺和地塞米松（DPd）方案后进行高剂量化疗-自体干细胞移植可带来更好的疗效。
Transplant Cell Ther. 2023 Apr;29(4):262.e1-262.e6. doi: 10.1016/j.jtct.2023.01.013. Epub 2023 Jan 20.

本文引用的文献

1
Impact of the Addition of Daratumumab to the Standard Bortezomib-Thalidomide-Dexamethasone Regimen on Hematopoietic Stem Cell Mobilization and Collection, Post-Transplant Engraftment and Infectious Complications: A Case-Control Multicentre Real-Life Analysis.在标准硼替佐米-沙利度胺-地塞米松方案中加入达雷妥尤单抗对造血干细胞动员与采集、移植后植入及感染并发症的影响：一项病例对照多中心真实世界分析
Mediterr J Hematol Infect Dis. 2024 May 1;16(1):e2024049. doi: 10.4084/MJHID.2024.049. eCollection 2024.
2
Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation.达雷妥尤单抗对多发性骨髓瘤患者自体干细胞移植中干细胞动员和采集、植入和移植后早期并发症的影响。
Leuk Lymphoma. 2023 Dec;64(13):2140-2147. doi: 10.1080/10428194.2023.2253479. Epub 2023 Sep 1.
3
CD38/ADP-ribose/TRPM2-mediated nuclear Ca signaling is essential for hepatic gluconeogenesis in fasting and diabetes.CD38/ADP-ribose/TRPM2 介导的核 Ca 信号对于禁食和糖尿病中的肝糖异生是必需的。
Exp Mol Med. 2023 Jul;55(7):1492-1505. doi: 10.1038/s12276-023-01034-9. Epub 2023 Jul 3.
4
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.修订版国际分期系统（R2-ISS）在多发性骨髓瘤整体生存中的应用：Harmony 项目下欧洲骨髓瘤网络（EMN）的报告。
J Clin Oncol. 2022 Oct 10;40(29):3406-3418. doi: 10.1200/JCO.21.02614. Epub 2022 May 23.
5
Update on primary plasma cell leukemia.原发性浆细胞白血病的最新进展。
Blood Res. 2022 Apr 30;57(S1):62-66. doi: 10.5045/br.2022.2022033.
6
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage.原发性浆细胞白血病：国际骨髓瘤工作组根据外周血浆细胞百分比的共识定义。
Blood Cancer J. 2021 Dec 2;11(12):192. doi: 10.1038/s41408-021-00587-0.
7
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.硼替佐米、沙利度胺和地塞米松联合或不联合达雷妥尤单抗用于新诊断多发性骨髓瘤患者自体造血干细胞移植前后（CASSIOPEIA）：一项随机、开放标签、3 期研究。
Lancet. 2019 Jul 6;394(10192):29-38. doi: 10.1016/S0140-6736(19)31240-1. Epub 2019 Jun 3.
8
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.多发性骨髓瘤修订国际分期系统：国际骨髓瘤工作组报告
J Clin Oncol. 2015 Sep 10;33(26):2863-9. doi: 10.1200/JCO.2015.61.2267. Epub 2015 Aug 3.